Full Text Journal Articles by
Author Kenneth F Grossmann


Find full text journal articles

Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial.

Alain P Algazi, Megan Othus, Adil I Daud, Roger S Lo, Janice M Mehnert, Thach-Giao Truong, Robert Conry, Kari Kendra, Gary C Doolittle, Joseph I Clark, Michael J Messino, Dennis F Moore, Christopher Lao, Bryan A Faller, Rangaswamy Govindarajan, Amy Harker-Murray, Luke Dreisbach, James Moon, Kenneth F Grossmann, Antoni Ribas,

Preclinical modeling suggests that intermittent BRAF inhibitor therapy may delay acquired resistance when blocking oncogenic BRAFV600 in melanoma1,2. We conducted S1320, a randomized, open-label, phase 2 clinical trial (NCT02196181) evaluating whether intermittent dosing of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib improves progression-free survival in patients with metastatic ... Read more >>

Nat Med (Nature medicine)
[2020, 26(10):1564-1568]

Cited: 0 times

View full text PDF listing >>

Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit.

Douglas Grossman, Nwanneka Okwundu, Edmund K Bartlett, Michael A Marchetti, Megan Othus, Daniel G Coit, Rebecca I Hartman, Sancy A Leachman, Elizabeth G Berry, Larissa Korde, Sandra J Lee, Menashe Bar-Eli, Marianne Berwick, Tawnya Bowles, Elizabeth I Buchbinder, Elizabeth M Burton, Emily Y Chu, Clara Curiel-Lewandrowski, Julia A Curtis, Adil Daud, Dekker C Deacon, Laura K Ferris, Jeffrey E Gershenwald, Kenneth F Grossmann, Siwen Hu-Lieskovan, John Hyngstrom, Joanne M Jeter, Robert L Judson-Torres, Kari L Kendra, Caroline C Kim, John M Kirkwood, David H Lawson, Philip D Leming, Georgina V Long, Ashfaq A Marghoob, Janice M Mehnert, Michael E Ming, Kelly C Nelson, David Polsky, Richard A Scolyer, Eric A Smith, Vernon K Sondak, Mitchell S Stark, Jennifer A Stein, John A Thompson, John F Thompson, Suraj S Venna, Maria L Wei, Susan M Swetter,

Importance:Use of prognostic gene expression profile (GEP) testing in cutaneous melanoma (CM) is rising despite a lack of endorsement as standard of care. Objective:To develop guidelines within the national Melanoma Prevention Working Group (MPWG) on integration of GEP testing into the management of patients with CM, including (1) review of ... Read more >>

JAMA Dermatol (JAMA dermatology)
[2020, :]

Cited: 0 times

View full text PDF listing >>


Comparative effectiveness of second-line ipilimumab vs. nivolumab in combination with ipilimumab in patients with advanced melanoma who received frontline anti-PD-1 antibodies.

Kelsey Baron, Justin C Moser, Shiven Patel, Kenneth F Grossmann, Sarah V Colonna, John R Hyngstrom,

INTRODUCTION:Anti-PD-1 antibodies are commonly used as frontline therapy for patients with metastatic melanoma. Although these medications can cause long term responses, a significant number of patients will not respond or will lose response. Optimal second-line therapy after losing response to anti-PD-1 antibodies is not well established. Therefore, we retrospectively compared ... Read more >>

J Oncol Pharm Pract (Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners)
[2020, :1078155220924719]

Cited: 0 times

View full text PDF listing >>

Comparative-effectiveness of pembrolizumab vs. nivolumab for patients with metastatic melanoma.

Justin C Moser, Guo Wei, Sarah V Colonna, Kenneth F Grossmann, Shiven Patel, John R Hyngstrom,

Background: Pembrolizumab (P) and nivolumab (N) are commonly used therapies for advanced melanoma. However, their effectiveness has never been directly compared, leaving little guidance for clinicians to select the best therapy. Therefore, we sought to retrospectively compare the overall survival of patients with metastatic melanoma treated with front line P ... Read more >>

Acta Oncol (Acta oncologica (Stockholm, Sweden))
[2020, 59(4):434-437]

Cited: 0 times

View full text PDF listing >>

Recurrence risk of early-stage melanoma of the external ear: an investigation of surgical approach and sentinel lymph node status.

Amanda Truong, John R Hyngstrom, Robert H I Andtbacka, R Dirk Noyes, Melissa Wright, John Snyder, Alyssa Winters, William T Sause, Kenneth F Grossmann, Hung T Khong, Glen M Bowen, Ying J Hitchcock, Douglas Grossman, Tawnya L Bowles,

Surgical management of external ear melanoma presents unique technical challenges based on the unique anatomy and reconstruction concerns. Surgical technique, including preservation of cartilage, is variable and impact on recurrence is unclear. Our goal was to investigate surgical approach, including extent of surgical resection and sentinel lymph node biopsy (SLNB), ... Read more >>

Melanoma Res. (Melanoma research)
[2020, 30(2):173-178]

Cited: 0 times

View full text PDF listing >>

Real-world survival of patients with advanced BRAF V600 mutated melanoma treated with front-line BRAF/MEK inhibitors, anti-PD-1 antibodies, or nivolumab/ipilimumab.

Justin C Moser, Danli Chen, Siwen Hu-Lieskovan, Kenneth F Grossmann, Shiven Patel, Sarah V Colonna, Jian Ying, John R Hyngstrom,

BACKGROUND:The optimal treatment sequence for patients with advanced BRAF V600 mutant melanoma is unknown. BRAF/MEK inhibition (BRAF/MEKi), single agent anti-PD-1 (aPD-1) antibodies and combination immune checkpoint inhibition with nivolumab and ipilimumab (niv/ipi) are all approved; however, they have not been prospectively compared. Therefore, we sought to compare overall survival of ... Read more >>

Cancer Med (Cancer medicine)
[2019, 8(18):7637-7643]

Cited: 5 times

View full text PDF listing >>

Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients with BRAF V600-mutant tumours.

Noelia Nebot, Hendrik-Tobias Arkenau, Jeffrey R Infante, Jason C Chandler, Andrew Weickhardt, Jason D Lickliter, John Sarantopoulos, Michael S Gordon, Gabriel Mak, Annie St-Pierre, Lihua Tang, Bijoyesh Mookerjee, Stanley W Carson, Siobhan Hayes, Kenneth F Grossmann,

AIMS:The effect of repeat oral supratherapeutic dosing of the BRAF inhibitor dabrafenib on QTc interval was assessed in patients with BRAF V600-mutant tumours. METHODS:Part 1 of this phase 1, multicentre, 2-part study (BRF113773/NCT01738451) assessed safety/tolerability of dabrafenib 225 or 300 mg twice daily (BID) to inform part 2 dosing. Patients in ... Read more >>

Br J Clin Pharmacol (British journal of clinical pharmacology)
[2018, 84(4):764-775]

Cited: 2 times

View full text PDF listing >>

Skin cancer screening: recommendations for data-driven screening guidelines and a review of the US Preventive Services Task Force controversy.

Mariah M Johnson, Sancy A Leachman, Lisa G Aspinwall, Lee D Cranmer, Clara Curiel-Lewandrowski, Vernon K Sondak, Clara E Stemwedel, Susan M Swetter, John Vetto, Tawnya Bowles, Robert P Dellavalle, Larisa J Geskin, Douglas Grossman, Kenneth F Grossmann, Jason E Hawkes, Joanne M Jeter, Caroline C Kim, John M Kirkwood, Aaron R Mangold, Frank Meyskens, Michael E Ming, Kelly C Nelson, Michael Piepkorn, Brian P Pollack, June K Robinson, Arthur J Sober, Shannon Trotter, Suraj S Venna, Sanjiv Agarwala, Rhoda Alani, Bruce Averbook, Anna Bar, Mirna Becevic, Neil Box, William E Carson, Pamela B Cassidy, Suephy C Chen, Emily Y Chu, Darrel L Ellis, Laura K Ferris, David E Fisher, Kari Kendra, David H Lawson, Philip D Leming, Kim A Margolin, Svetomir Markovic, Mary C Martini, Debbie Miller, Debjani Sahni, William H Sharfman, Jennifer Stein, Alexander J Stratigos, Ahmad Tarhini, Matthew H Taylor, Oliver J Wisco, Michael K Wong,

Melanoma is usually apparent on the skin and readily detected by trained medical providers using a routine total body skin examination, yet this malignancy is responsible for the majority of skin cancer-related deaths. Currently, there is no national consensus on skin cancer screening in the USA, but dermatologists and primary ... Read more >>

(Melanoma management)
[2017, 4(1):13-37]

Cited: 17 times

View full text PDF listing >>

Treatment-related determinants of survival in early-stage (T1-2N0M0) oral cavity cancer: A population-based study.

Justin C Sowder, Richard B Cannon, Luke O Buchmann, Jason P Hunt, Ying Hitchcock, Shane Lloyd, Kenneth F Grossmann, Marcus M Monroe,

National guidelines support both surgical and radiotherapy (RT) as initial treatment options for early-stage oral cavity squamous cell carcinoma (SCC). There remains limited data evaluating the survival outcomes of RT and the current practice patterns for these lesions.We conducted a retrospective review of 8274 patients in the Surveillance, Epidemiology, and ... Read more >>

Head Neck (Head & neck)
[2017, 39(5):876-880]

Cited: 13 times

View full text PDF listing >>

Extension of overall survival beyond objective responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2.

David D Stenehjem, Michael Toole, Joseph Merriman, Kinjal Parikh, Stephanie Daignault, Sarah Scarlett, Peg Esper, Katherine Skinner, Aaron Udager, Srinivas Kiran Tantravahi, David Gill, Alli M Straubhar, Archana M Agarwal, Kenneth F Grossmann, Wolfram E Samlowski, Bruce Redman, Neeraj Agarwal, Ajjai Alva,

In metastatic renal cell carcinoma (mRCC), survival benefit associated with objective response rates of 16-20 % with high-dose interleukin-2 (HDIL-2) is well established and discussed. Based on recently emerged data on efficacy of cancer immunotherapy, we hypothesized that the survival benefit with HDIL-2 extends beyond those achieving objective responses, i.e., to ... Read more >>

Cancer Immunol. Immunother. (Cancer immunology, immunotherapy : CII)
[2016, 65(8):941-949]

Cited: 7 times

View full text PDF listing >>

A phase 2 study of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Antonio Jimeno, Marshall R Posner, Lori J Wirth, Nabil F Saba, Roger B Cohen, Elizabeta C Popa, Athanassios Argiris, Kenneth F Grossmann, Ammar Sukari, Dawn Wilson, Xiaosha Zhang, Jade Sun, Chad Glasser, Kenneth M Attie, Matthew L Sherman, Susan S Pandya, Jared Weiss,

BACKGROUND:Patients with platinum-refractory, recurrent or metastatic squamous cell carcinoma of the head and neck (RM-SCCHN) have limited options. Activin receptor-like kinase 1 (ALK1) is a type I receptor of the transforming growth factor β superfamily expressed on activated endothelial cells. Dalantercept is an ALK1 receptor fusion protein that acts as ... Read more >>

Cancer (Cancer)
[2016, 122(23):3641-3649]

Cited: 12 times

View full text PDF listing >>

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.

F Stephen Hodi, Jason Chesney, Anna C Pavlick, Caroline Robert, Kenneth F Grossmann, David F McDermott, Gerald P Linette, Nicolas Meyer, Jeffrey K Giguere, Sanjiv S Agarwala, Montaser Shaheen, Marc S Ernstoff, David R Minor, April K Salama, Matthew H Taylor, Patrick A Ott, Christine Horak, Paul Gagnier, Joel Jiang, Jedd D Wolchok, Michael A Postow,

BACKGROUND:Results from phase 2 and 3 trials in patients with advanced melanoma have shown significant improvements in the proportion of patients achieving an objective response and prolonged progression-free survival with the combination of nivolumab (an anti-PD-1 antibody) plus ipilimumab (an anti-CTLA-4 antibody) compared with ipilimumab alone. We report 2-year overall ... Read more >>

Lancet Oncol. (The Lancet. Oncology)
[2016, 17(11):1558-1568]

Cited: 284 times

View full text PDF listing >>

A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma.

Abhijit Ray, Matthew A Williams, Stephanie M Meek, Randy C Bowen, Kenneth F Grossmann, Robert H I Andtbacka, Tawnya L Bowles, John R Hyngstrom, Sancy A Leachman, Douglas Grossman, Glen M Bowen, Sheri L Holmen, Matthew W VanBrocklin, Gita Suneja, Hung T Khong,

Intratumoral interleukin-2 (IL-2) is effective but does not generate systemic immunity. Intravenous ipilimumab produces durable clinical response in a minority of patients, with potentially severe toxicities. Circulating anti-tumor T cells activated by ipilimumab may differ greatly from tumor-infiltrating lymphocytes activated by intratumoral ipilimumab in phenotypes and functionality. The objective of ... Read more >>

Oncotarget (Oncotarget)
[2016, 7(39):64390-64399]

Cited: 12 times

View full text PDF listing >>

Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG).

Christopher J Anker, Kenneth F Grossmann, Michael B Atkins, Gita Suneja, Ahmad A Tarhini, John M Kirkwood,

BRAF kinase gene V600 point mutations drive approximately 40% to 50% of all melanomas, and BRAF inhibitors (BRAFi) have been found to significantly improve survival outcomes. Although radiation therapy (RT) provides effective symptom palliation, there is a lack of toxicity and efficacy data when RT is combined with BRAFi, including ... Read more >>

Int. J. Radiat. Oncol. Biol. Phys. (International journal of radiation oncology, biology, physics)
[2016, 95(2):632-646]

Cited: 19 times

View full text PDF listing >>

Detection of Exosomal miRNAs in the Plasma of Melanoma Patients.

Susan R Pfeffer, Kenneth F Grossmann, Pamela B Cassidy, Chuan He Yang, Meiyun Fan, Levy Kopelovich, Sancy A Leachman, Lawrence M Pfeffer,

MicroRNAs (miRNAs) are a class of 22-25 nucleotide RNAs that control gene expression at the post-transcriptional level. MiRNAs have potential as cancer biomarkers. Melanoma is a highly aggressive form of skin cancer accounting for almost 4% of cancers among men and women, and ~80% of skin cancer-related deaths in the ... Read more >>

(Journal of clinical medicine)
[2015, 4(12):2012-2027]

Cited: 42 times

View full text PDF listing >>

Adjuvant treatment for patients with surgically resected advanced-stage melanoma.

Kenneth F Grossmann,

Clin Adv Hematol Oncol (Clinical advances in hematology & oncology : H&O)
[2015, 13(10):633-635]

Cited: 0 times

View full text PDF listing >>

Local control after stereotactic radiosurgery for brain metastases in patients with melanoma with and without BRAF mutation and treatment.

David Ly, Hilary P Bagshaw, Christopher J Anker, Jonathan D Tward, Kenneth F Grossmann, Randy L Jensen, Dennis C Shrieve,

BRAF inhibitors improve progression-free and overall survival in patients with metastatic melanoma. Brain metastases are common, and stereotactic radiosurgery (SRS) has been used, resulting in excellent local control. Because BRAF inhibitors are associated with intracranial responses, the authors hypothesized that BRAF inhibitors would improve local control in patients with melanoma ... Read more >>

J Neurosurg (Journal of neurosurgery)
[2015, 123(2):395-401]

Cited: 25 times

View full text PDF listing >>

Assessment of the drug interaction potential and single- and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenib.

A Benjamin Suttle, Kenneth F Grossmann, Daniele Ouellet, Lauren E Richards-Peterson, Gursel Aktan, Michael S Gordon, Patricia M LoRusso, Jeffrey R Infante, Sunil Sharma, Kari Kendra, Manish Patel, Shubham Pant, Hendrik-Tobias Arkenau, Mark R Middleton, Samuel C Blackman, Jeff Botbyl, Stanley W Carson,

The induction of CYP2C9 by dabrafenib using S-warfarin as a probe and the effects of a CYP3A inhibitor (ketoconazole) and a CYP2C8 inhibitor (gemfibrozil) on dabrafenib pharmacokinetics were evaluated in patients with BRAF V600 mutation-positive tumors. Dabrafenib single- and repeat-dose pharmacokinetics were also evaluated. S-warfarin AUC(0- ∞) decreased 37% and ... Read more >>

J Clin Pharmacol (Journal of clinical pharmacology)
[2015, 55(4):392-400]

Cited: 10 times

View full text PDF listing >>

Long-term survival as a treatment benchmark in melanoma: latest results and clinical implications.

Kenneth F Grossmann, Kim Margolin,

Historically, stage III-IV melanoma patients have had few options to achieve long-term survival. For patients with stage III disease, surgery alone may be curative for approximately 50%. Adjuvant treatment with a slightly greater impact on relapse-free survival at the cost of substantial toxicity, and studies are ongoing to test the ... Read more >>

(Therapeutic advances in medical oncology)
[2015, 7(3):181-191]

Cited: 8 times

View full text PDF listing >>

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

Jeffrey S Weber, Sandra P D'Angelo, David Minor, F Stephen Hodi, Ralf Gutzmer, Bart Neyns, Christoph Hoeller, Nikhil I Khushalani, Wilson H Miller, Christopher D Lao, Gerald P Linette, Luc Thomas, Paul Lorigan, Kenneth F Grossmann, Jessica C Hassel, Michele Maio, Mario Sznol, Paolo A Ascierto, Peter Mohr, Bartosz Chmielowski, Alan Bryce, Inge M Svane, Jean-Jacques Grob, Angela M Krackhardt, Christine Horak, Alexandre Lambert, Arvin S Yang, James Larkin,

Nivolumab, a fully human IgG4 PD-1 immune checkpoint inhibitor antibody, can result in durable responses in patients with melanoma who have progressed after ipilimumab and BRAF inhibitors. We assessed the efficacy and safety of nivolumab compared with investigator's choice of chemotherapy (ICC) as a second-line or later-line treatment in patients ... Read more >>

Lancet Oncol. (The Lancet. Oncology)
[2015, 16(4):375-384]

Cited: 948 times

View full text PDF listing >>

Clinical outcomes associated with evolving treatment modalities and radiation techniques for base-of-tongue carcinoma: thirty years of institutional experience.

Leechuan Andy Chen, Christopher J Anker, Jason P Hunt, Luke O Buchmann, Kenneth F Grossmann, Kenneth Boucher, Li-Ming Christine Fang, Dennis C Shrieve, Ying J Hitchcock,

Curative treatment for base-of-tongue squamous cell carcinoma (BOT SCC) has evolved over time; however, comparative outcomes analysis for various treatment strategies is lacking. The authors reviewed the evolution of treatment modality and radiotherapy (RT) technique for 231 consecutive BOT SCC patients at our institution between 1981 and 2011. Treatment modalities ... Read more >>

Cancer Med (Cancer medicine)
[2015, 4(5):651-660]

Cited: 6 times

View full text PDF listing >>

Sustained remission of Parkinson disease associated melanoma with immunotherapy.

David R Shprecher, Kenneth F Grossmann, Jonathan D Tward,

Parkinsonism Relat Disord (Parkinsonism & related disorders)
[2014, 20(9):1027-1029]

Cited: 1 time

View full text PDF listing >>

Patterns of failure and predictors of outcome in cutaneous malignant melanoma of the scalp.

Breanne E Terakedis, Christopher J Anker, Sancy A Leachman, Robert H I Andtbacka, Glen M Bowen, William T Sause, Kenneth F Grossmann, Tawnya L Bowles, R Dirk Noyes, Ying J Hitchcock, Kenneth M Boucher, Dennis C Shrieve,

BACKGROUND: Patients with melanoma of the scalp may have higher failure (recurrence) rates than melanoma of other body sites. OBJECTIVE: We sought to characterize survival and patterns of failure for patients with scalp melanoma. METHODS: Between 1998 and 2010, 250 nonmetastatic patients underwent wide local excision of a primary scalp ... Read more >>

J. Am. Acad. Dermatol. (Journal of the American Academy of Dermatology)
[2014, 70(3):435-442]

Cited: 5 times

View full text PDF listing >>

Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma.

Christopher J Anker, Antoni Ribas, Allie H Grossmann, Xinjian Chen, Krishna K Narra, Wallace Akerley, Robert H I Andtbacka, Robert Dirk Noyes, Dennis C Shrieve, Kenneth F Grossmann,

J. Clin. Oncol. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2013, 31(17):e283-7]

Cited: 41 times

View full text PDF listing >>

Phase I trial of verubulin (MPC-6827) plus carboplatin in patients with relapsed glioblastoma multiforme.

Kenneth F Grossmann, Howard Colman, Wallace A Akerley, Michael Glantz, Yuko Matsuoko, Andrew P Beelen, Margaret Yu, John F De Groot, Robert D Aiken, Jeffrey J Olson, Brent A Evans, Randy L Jensen,

Verubulin (MPC-6827) is a microtubule-destabilizing agent that achieves high concentrations in the brain. Verubulin disrupts newly formed blood vessels in xenografts. We determined the safety and tolerability of verubulin administered in combination with carboplatin in patients with relapsed glioblastoma multiforme (GBM). Three pre-selected doses of verubulin were tested: 2.1, 2.7, ... Read more >>

J. Neurooncol. (Journal of neuro-oncology)
[2012, 110(2):257-264]

Cited: 8 times

View full text PDF listing >>


1.1188 s